Pharmacological approaches to treat intestinal pain

References

• Woolf CJ. What is this thing called pain? J Clin Invest. 2010;120:3742–3744.
   PubMed Web of Science ®Google Scholar
• Raja SN, Carr DB, Cohen M, et al. The revised international association for the study of pain definition of pain: concepts, challenges, and compromises. Pain. 2020;161:1976–1982.
   PubMed Web of Science ®Google Scholar
• Cascella M, Muzio MR, Monaco F, et al. Pathophysiology of nociception and rare genetic disorders with increased pain threshold or pain insensitivity. Pathophysiol off J Int Soc Pathophysiol. 2022;29:435–452.
   PubMedGoogle Scholar
• Macaluso C, McNamara RM. Evaluation and management of acute abdominal pain in the emergency department. Int J Gen Med. 2012;789. DOI:10.2147/IJGM.S25936
   PubMedGoogle Scholar
• Paine P. Review article: current and future treatment approaches for pain in IBS. Aliment Pharmacol Ther. 2021;54(Suppl 1):S75–88. 10.1111/apt.16550
   PubMedGoogle Scholar
• Sinopoulou V, Gordon M, Akobeng AK, et al. Interventions for the management of abdominal pain in Crohn’s disease and inflammatory bowel disease. Cochrane Database Syst Rev. 2021;11:CD013531.
   PubMedGoogle Scholar
• Le Berre C, Peyrin-Biroulet L, Buisson A, et al. Impact of inflammatory bowel diseases on working life: a French nationwide survey. Dig Liver Dis. 2019;51:961–966.
   PubMedGoogle Scholar
• Paulides E, Cornelissen D, de Vries AC, et al. Inflammatory bowel disease negatively impacts household and family life. Frontline Gastroenterol. 2022;13:402–408.
   PubMedGoogle Scholar
• Weaver E, Szigethy E. Managing pain and psychosocial care in IBD: a primer for the practicing gastroenterologist. Curr Gastroenterol Rep. 2020;22:20.
   PubMedGoogle Scholar
• Bilski J, Wojcik D, Danielak A, et al. Alternative therapy in the prevention of experimental and clinical inflammatory bowel disease. impact of regular physical activity, intestinal alkaline phosphatase and herbal products. Curr Pharm Des. 2020;26:2936–2950.
   PubMedGoogle Scholar
• Ballantyne JC, Kalso E, Stannard C. WHO analgesic ladder: a good concept gone astray. BMJ England. 2016;i20. DOI:10.1136/bmj.i20
   PubMedGoogle Scholar
• Dalal S, Bruera E. Management of pain in the cancer patient. Front Pain Res (Lausanne, Switzerland). 2022;3:926712.
   PubMedGoogle Scholar
• Mitra R, Jones S. Adjuvant Analgesics in Cancer Pain: a Review. Am J Hosp Palliat Med. 2012;29:70–79.
   PubMed Web of Science ®Google Scholar
• Bonnesen K, Schmidt M. Recategorization of non-aspirin nonsteroidal anti-inflammatory drugs according to clinical relevance: abandoning the traditional NSAID terminology. Can J Cardiol. 2021;37:37.
   PubMedGoogle Scholar
• Doostmohammadi M, Rahimi HR. ADME and toxicity considerations for tramadol: from basic research to clinical implications. Expert Opin Drug Metab Toxicol. 2020;16:627–640.
   PubMed Web of Science ®Google Scholar
• Manirakiza A, Irakoze L, Manirakiza S, et al. Efficacy and safety of fentanyl compared with morphine among adult patients with cancer: a meta-analysis. East African Heal Res J. 2020;4:8–16.
   PubMedGoogle Scholar
• Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78:1211–1228.
   PubMed Web of Science ®Google Scholar
• Yang J, Bauer BA, Wahner-Roedler DL, et al. The modified WHO analgesic ladder: is it appropriate for chronic non-cancer pain? J Pain Res. 2020;13:411–417.
   PubMed Web of Science ®Google Scholar
• Choung RS, Locke GR3rd author. Epidemiology of IBS. Gastroenterol Clin North Am. 2011;40:1–10.
   PubMed Web of Science ®Google Scholar
• Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg. 2012;25:46–52.
   PubMedGoogle Scholar
• Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20:6759–6773.
   PubMed Web of Science ®Google Scholar
• Chen L, Ilham SJ, Feng B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesthesiol Pain Med. 2017;7:e42747.
   PubMedGoogle Scholar
• Farmer AD, Ferdinand E, Aziz Q. Opioids and the gastrointestinal tract - a case of narcotic bowel syndrome and literature review. J Neurogastroenterol Motil. 2013;19:94–98.
   PubMed Web of Science ®Google Scholar
• Martínez-Vázquez MA, Vázquez-Elizondo G, González-González JA, et al. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Rev Gastroenterol México. 2012;77:82–90.
   PubMedGoogle Scholar
• Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, et al. The efficacy of mebeverine in the treatment of irritable bowel syndrome—A systematic review. J Clin Med. 2022;11:11.
   Google Scholar
• Bor S, Lehert P, Chalbaud A, et al. Efficacy of pinaverium bromide in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211033740.
   Google Scholar
• Ingrosso MR, Ianiro G, Nee J, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Aliment Pharmacol Ther. 2022;56:932–941.
   PubMedGoogle Scholar
• Fond G, Loundou A, Hamdani N, et al. Anxiety and depression comorbidities in Irritable Bowel Syndrome (IBS): a Systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014;264:651–660.
   PubMed Web of Science ®Google Scholar
• Kułak-Bejda A, Bejda G, Waszkiewicz N. Antidepressants for irritable bowel syndrome—A systematic review. Pharmacol Rep. 2017;69:1366–1379.
   PubMed Web of Science ®Google Scholar
• Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:117–131.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc. 2018;93:1858–1872.
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, et al. Expert consensus document. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–514.
   PubMed Web of Science ®Google Scholar
• Hyland NP, Quigley EMM, Brint E. Microbiota-host interactions in irritable bowel syndrome: epithelial barrier, immune regulation and brain-gut interactions. World J Gastroenterol. 2014;20:8859–8866.
   PubMedGoogle Scholar
• Zeng J, Li YQ, Zuo XL, et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2008;28:994–1002.
   PubMed Web of Science ®Google Scholar
• Simon E, Călinoiu LF, Mitrea L, et al. Probiotics, prebiotics, and synbiotics: implications and beneficial effects against irritable bowel syndrome. Nutrients. 2021;13:2112.
   PubMedGoogle Scholar
• Lavö B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome–a double-blind placebo controlled study. Scand J Gastroenterol Suppl. 1987;130:77–80.
   PubMedGoogle Scholar
• Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable bowel syndrome with diarrhea. N Engl J Med. 2016;374:242–253.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205–217.
   PubMed Web of Science ®Google Scholar
• Brand S. Crohn’s disease: th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 2009;58:1152–1167.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–9.
   PubMed Web of Science ®Google Scholar
• Zeitz J, Ak M, Müller-Mottet S, et al. Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLoS ONE. 2016;11:e0156666.
   PubMed Web of Science ®Google Scholar
• Norton C, Czuber-Dochan W, Artom M, et al. Systematic review: interventions for abdominal pain management in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46:115–125.
   PubMed Web of Science ®Google Scholar
• Basso L, Bourreille A, Dietrich G. Intestinal inflammation and pain management. Curr Opin Pharmacol. 2015;25:50–55.
   PubMed Web of Science ®Google Scholar
• Noureldin M, Higgins PDR, Govani SM, et al. Incidence and predictors of new persistent opioid use following inflammatory bowel disease flares treated with oral corticosteroids. Aliment Pharmacol Ther. 2019;49:74–83.
   PubMed Web of Science ®Google Scholar
• Madl C, Druml W. Systemic consequences of ileus. Best Pract Res Clin Gastroenterol. 2003;17:445–456.
   PubMedGoogle Scholar
• Lie MRKL, van der Giessen J, Fuhler GM, et al. Low dose naltrexone for induction of remission in inflammatory bowel disease patients. J Transl Med. 2018;16:55.
   PubMedGoogle Scholar
• Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep. 2020;24:64.
   PubMedGoogle Scholar
• Lakhan SE, Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J Neuroinflammation. 2010;7:37.
   PubMed Web of Science ®Google Scholar
• Sostres C, Gargallo CJ, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther. 2013;15(Suppl 3):S3.
   PubMed Web of Science ®Google Scholar
• Evans JM, McMahon AD, Murray FE, et al. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40:619–622.
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for crohn disease and ulcerative colitis: a cohort study. Ann Intern Med. 2012;156:350–359.
   PubMed Web of Science ®Google Scholar
• Moninuola OO, Milligan W, Lochhead P, et al. Systematic review with meta-analysis: association between acetaminophen and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) and risk of crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018;47:1428–1439.
   PubMedGoogle Scholar
• Docherty MJ, Jones RCW, Wallace MS. Managing pain in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7:592–601.
   PubMedGoogle Scholar
• Mikocka-Walus A, Ford AC, Drossman DA. Antidepressants in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17:184–192.
   PubMedGoogle Scholar
• Macer BJD, Prady SL, Mikocka-Walus A. Antidepressants in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2017;23:534–550.
   PubMed Web of Science ®Google Scholar
• Martyniak A, Medyńska-Przęczek A, Wędrychowicz A, et al. Prebiotics, probiotics, synbiotics, paraprobiotics and postbiotic compounds in IBD. Biomolecules. 2021;11:1–24.
   Google Scholar
• Gibson GR. Roberfroid MB dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401–1412.
   PubMed Web of Science ®Google Scholar
• Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019;16:605–616.
   PubMed Web of Science ®Google Scholar
• Benjamin JL, Hedin CRH, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active crohn’s disease. Gut. 2011;60:923–929.
   PubMed Web of Science ®Google Scholar
• Yılmaz İ, Dolar ME, Özpınar H. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: a randomized controlled trial. Turkish J Gastroenterol off J Turkish Soc Gastroenterol. 2019;30:242–253.
   PubMed Web of Science ®Google Scholar
• Dore MP, Bibbò S, Fresi G, et al. Side effects associated with probiotic use in adult patients with inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2019;11:1–12.
   Google Scholar
• Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215–226.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for crohn’s disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24:490–501.
   PubMedGoogle Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2013;369:711–721.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Lasch K, Lissoos T, et al. Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2019;17:130–138.e7.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5:819–828.
   PubMed Web of Science ®Google Scholar
• Becher N, Swaminath A, Sultan K. A literature review of ozanimod therapy in inflammatory bowel disease: from concept to practical application. Ther Clin Risk Manag. 2022;18:913–927.
   PubMed Web of Science ®Google Scholar
• Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2012;107:1474–1482.
   PubMed Web of Science ®Google Scholar
• Zielińska A, Włodarczyk M, Makaro A, et al. Management of pain in colorectal cancer patients. Crit Rev Oncol Hematol. 2021;157:103122.
   PubMedGoogle Scholar
• Portenoy RK. Treatment of cancer pain. Lancet (London, England). 2011;377:2236–2247.
   PubMed Web of Science ®Google Scholar
• Renna ME, Shrout MR, Madison AA, et al. Depression and anxiety in colorectal cancer patients: ties to pain, fatigue, and inflammation. Psychooncology. 2022;31:1536–1544.
   PubMedGoogle Scholar
• Cuomo A, Cascella M, Forte CA, et al. Careful breakthrough cancer pain treatment through rapid-onset transmucosal fentanyl improves the quality of life in cancer patients: results from the BEST multicenter study. J Clin Med. 2020;9:1003.
   PubMedGoogle Scholar
• Brown MR, Ramirez JD, Farquhar-Smith P. Pain in cancer survivors. Br J. 2014;8:139–153. pain.
   Google Scholar
• Peng S, Ying AF, Chan NJH, et al. Prevention of oxaliplatin-induced peripheral neuropathy: a systematic review and meta-analysis. Front Oncol. 2022;12:731223.
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore RA, et al. Oral Paracetamol (Acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017;7:CD012637.
   PubMedGoogle Scholar
• Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Transl Hepatol. 2016;4:131–142.
   PubMed Web of Science ®Google Scholar
• Derry S, Wiffen PJ, Moore RA, et al. Oral Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) for cancer pain in adults. Cochrane Database Syst Rev. 2017;7:CD012638.
   PubMedGoogle Scholar
• Cannon CP, Cannon PJ. Physiology. COX-2 inhibitors and cardiovascular risk. Science. 2012;336:1386–1387.
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Derry S, Moore RA. Tramadol with or without paracetamol (Acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017;5:CD012508.
   PubMedGoogle Scholar
• Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology. 2011;87:274–285.
   PubMed Web of Science ®Google Scholar
• Armstrong SC, Cozza KL. Pharmacokinetic Drug Interactions of Morphine, Codeine, and Their Derivatives: theory and Clinical Reality, Part II. Psychosomatics. 2003;44:515–520.
   PubMed Web of Science ®Google Scholar
• Leppert W, Majkowicz M. The impact of tramadol and dihydrocodeine treatment on quality of life of patients with cancer pain. Int J Clin Pract. 2010;64:1681–1687.
   PubMed Web of Science ®Google Scholar
• Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database Syst Rev. 2013;3:CD003868.
   Google Scholar
• Chung C. Pharmacologic management of cancer-related pain. Cancer Control. 2021;22(4):412–425.
   Google Scholar
• Nosek K, Leppert W, Nosek H, et al. A Comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. Drug Des Devel Ther. 2017;11:2409–2419.
   PubMed Web of Science ®Google Scholar
• Kumar R, Viswanath O, Saadabadi A. Buprenorphine. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Good P, Afsharimani B, Movva R, et al. Therapeutic challenges in cancer pain management: a systematic review of methadone. J Pain Palliat Care Pharmacother. 2014;28:197–205.
   PubMedGoogle Scholar
• Attal N. Pharmacological treatments of neuropathic pain: the latest recommendations. Rev Neurol (Paris). 2019;175:46–50.
   PubMed Web of Science ®Google Scholar
• Sobolewska-Włodarczyk A, Włodarczyk M, Storr M, et al. Clinical potential of eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. Ther Clin Risk Manag. 2016;12:771–775.
   PubMed Web of Science ®Google Scholar
• Pedersen SF, Owsianik G, Nilius B. TRP channels: an overview. Cell Calcium. 2005;38:233–252.
   PubMed Web of Science ®Google Scholar
• Ng QX, Sen SA, Loke W, et al. The role of inflammation in Irritable Bowel Syndrome (IBS). J Inflamm Res. 2018;11:345–349.
   PubMed Web of Science ®Google Scholar
• Filippova LV, Bystrova EY, Malyshev FS, et al. Expression of pattern recognition receptors by nociceptive metasympathetic neurons. Bull Exp Biol Med. 2015;159:248–252.
   PubMedGoogle Scholar
• Zielińska M, Jarmuz A, Wasilewski A, et al. Role of Transient receptor potential channels in intestinal inflammation and visceral pain: novel targets in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:419–427.
   PubMedGoogle Scholar
• Csekő K, Beckers B, Keszthelyi D, et al. Role of TRPV1 and TRPA1 ion channels in inflammatory bowel diseases: potential therapeutic targets? Pharmaceuticals. 2019;12:48.
   Google Scholar
• Perna E, Aguilera-Lizarraga J, Florens MV, et al. Effect of resolvins on sensitisation of trpv1 and visceral hypersensitivity in IBS. Gut. 2021;70:1275–1286.
   PubMed Web of Science ®Google Scholar
• Iftinca M, Defaye M, Altier C. TRPV1-targeted drugs in development for human pain conditions. Drugs. 2021;81:7–27.
   PubMedGoogle Scholar
• Feng Y, Zhu Y, Wan J, et al. Enhanced oral bioavailability, reduced irritation and increased hypolipidemic activity of self-assembled capsaicin prodrug nanoparticles. J Funct Foods. 2018;44:137–145.
   Web of Science ®Google Scholar
• Smutzer G, Jacob JC, Tran JT, et al. Detection and modulation of capsaicin perception in the human oral cavity. Physiol Behav. 2018;194:120–131.
   PubMed Web of Science ®Google Scholar
• Gonlachanvit S, Mahayosnond A, Kullavanijaya P. Effects of chili on postprandial gastrointestinal symptoms in diarrhoea predominant irritable bowel syndrome: evidence for capsaicin-sensitive visceral nociception hypersensitivity. Neurogastroenterol Motil off J Eur Gastrointest Motil Soc. 2009;21:23–32.
   PubMed Web of Science ®Google Scholar
• Lu M, Chen C, Lan Y, et al. Capsaicin - the major bioactive ingredient of chili peppers: bio-efficacy and delivery systems. Food Funct. 2020;11:2848–2860.
   PubMed Web of Science ®Google Scholar
• Sb-705498 rectal pain study. Available from: https://www.clinicaltrials.gov/ct2/show/NCT00461682.
   Google Scholar
• Wouters MM, Balemans D, Van Wanrooy S, et al. Histamine receptor H1-mediated sensitization of TRPV1 mediates visceral hypersensitivity and symptoms in patients with irritable bowel syndrome. Gastroenterology. 2016;150:875–87.e9.
   PubMed Web of Science ®Google Scholar
• Kun J, Szitter I, Kemény Á, et al. Upregulation of the transient receptor potential ankyrin 1 ion channel in the inflamed human and mouse colon and its protective roles. PLoS ONE. 2014;9:e108164.
   PubMedGoogle Scholar
• Bernardini M, Fiorio Pla A, Prevarskaya N, et al. Human Transient Receptor Potential (TRP) channel expression profiling in carcinogenesis. Int J Dev Biol. 2015;59:399–406.
   PubMed Web of Science ®Google Scholar
• Andersson DA, Gentry C, Moss S, et al. Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci off J Soc Neurosci. 2008;28:2485–2494.
   PubMed Web of Science ®Google Scholar
• Yang J, Li Y, Zuo X, et al. Transient receptor potential ankyrin-1 participates in visceral hyperalgesia following experimental colitis. Neurosci Lett. 2008;440:237–241.
   PubMed Web of Science ®Google Scholar
• Balemans D, Aguilera-Lizarraga J, Florens MV, et al. Histamine-mediated potentiation of Transient Receptor Potential (TRP) ankyrin 1 and TRP vanilloid 4 signaling in submucosal neurons in patients with irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2019;316:G338–349.
   PubMed Web of Science ®Google Scholar
• Desmet M, Vander Cruyssen P, Pottel H, et al. The influence of propofol and sevoflurane on intestinal motility during laparoscopic surgery. Acta Anaesthesiol Scand. 2016;60:335–342.
   PubMedGoogle Scholar
• Hiraishi K, Kurahara L-H, Sumiyoshi M, et al. Daikenchuto (Da-Jian-Zhong-Tang) ameliorates intestinal fibrosis by activating myofibroblast transient receptor potential ankyrin 1 channel. World J Gastroenterol. 2018;24:4036–4053.
   PubMed Web of Science ®Google Scholar
• Mueller-Tribbensee SM, Karna M, Khalil M, et al. Differential contribution of TRPA1, TRPV4 and TRPM8 to colonic nociception in mice. PLoS ONE. 2015;10:e0128242.
   PubMedGoogle Scholar
• Hosoya T, Matsumoto K, Tashima K, et al. TRPM8 has a key role in experimental colitis-induced visceral hyperalgesia in mice. Neurogastroenterol Motil off J Eur Gastrointest Motil Soc. 2014;26:1112–1121.
   PubMedGoogle Scholar
• Beckers AB, Weerts ZZRM, Helyes Z, et al. Review article: transient receptor potential channels as possible therapeutic targets in irritable bowel syndrome. Aliment Pharmacol Ther. 2017;46:938–952.
   PubMed Web of Science ®Google Scholar
• Hasenoehrl C, Taschler U, Storr M, et al. The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease. Neurogastroenterol Motil off J Eur Gastrointest Motil Soc. 2016;28:1765–1780.
   PubMed Web of Science ®Google Scholar
• Grill M, Hasenoehrl C, Kienzl M, et al. Cellular localization and regulation of receptors and enzymes of the endocannabinoid system in intestinal and systemic inflammation. Histochem Cell Biol. 2019;151:5–20.
   PubMedGoogle Scholar
• Leo LM, Abood ME. CB1 cannabinoid receptor signaling and biased signaling. Molecules. 2021;26(17):5413.
   PubMedGoogle Scholar
• Mahmud A, Santha P, Paule CC, et al. Cannabinoid 1 receptor activation inhibits transient receptor potential vanilloid type 1 receptor-mediated cationic influx into rat cultured primary sensory neurons. Neuroscience. 2009;162:1202–1211.
   PubMed Web of Science ®Google Scholar
• Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005;129:437–453.
   PubMed Web of Science ®Google Scholar
• Karwad MA, Couch DG, Theophilidou E, et al. The role of CB(1) in intestinal permeability and inflammation. FASEB J Off Publ Fed Am Soc Exp Biol. 2017;31:3267–3277.
   PubMedGoogle Scholar
• Acharya N, Penukonda S, Shcheglova T, et al. Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proc Natl Acad Sci U S A. 2017;114:5005–5010.
   PubMed Web of Science ®Google Scholar
• Hillsley K, McCaul C, Aerssens J, et al. Activation of the Cannabinoid 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil off J Eur Gastrointest Motil Soc. 2007;19:769–777.
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13:35–37.
   PubMed Web of Science ®Google Scholar
• Brierley SM, Greenwood-Van Meerveld B, Sarnelli G, et al. Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome. Nat Rev Gastroenterol Hepatol. 2023;20:5–25.
   PubMedGoogle Scholar
• Feng C-C, Yan X-J, Chen X, et al. Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats. Pain. 2014;155:1591–1604.
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Battista N, Biancheri P, et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. Mucosal Immunol. 2011;4:574–583.
   PubMed Web of Science ®Google Scholar
• Tartakover Matalon S, Azar S, Meiri D. Endocannabinoid Levels in ulcerative colitis patients correlate with clinical parameters and are affected by cannabis consumption. Front Endocrinol. 2021;12:685289.
   PubMedGoogle Scholar
• Fichna J, Sałaga M, Stuart J, et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol Motil off J Eur Gastrointest Motil Soc. 2014;26:470–481.
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Lambert DM, Delzenne NM, et al. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J Off Publ Fed Am Soc Exp Biol. 2011;25:2711–2721.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Gao J, Yin Z-Z, et al. Dual-drug delivery system based on the hydrogels of alginate and sodium carboxymethyl cellulose for colorectal cancer treatment. Carbohydr Polym. 2021;269:118325.
   PubMed Web of Science ®Google Scholar
• Wasay SA, Jan SU, Akhtar M, et al. Developed meloxicam loaded microparticles for colon targeted delivery: statistical optimization, physicochemical characterization, and in-vivo toxicity study. PLoS ONE. 2022;17:e0267306.
   PubMedGoogle Scholar
• Siuda ER, Carr R 3rd, Rominger DH, et al. Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol. 2017;32:77–84.
   PubMed Web of Science ®Google Scholar
• Goudra B. Oliceridine- opioid of the 21(st) century. Saudi J Anaesth. 2022;16:69–75.
   PubMedGoogle Scholar
• Martínez V, Abalo R. Peripherally acting opioid analgesics and peripherally-induced analgesia. Behav Pharmacol. 2020;31:136–158.
   PubMedGoogle Scholar
• Szarka LA, Camilleri M, Burton D, et al. Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2007;5:1268–1275.
   PubMed Web of Science ®Google Scholar
• Machelska H, Celik MÖ. Advances in achieving opioid analgesia without side effects. Front Pharmacol. 2018;9:1388.
   PubMedGoogle Scholar
• Mas-Orea X, Basso L, Blanpied C, et al. Delta opioid receptors on nociceptive sensory neurons mediate peripheral endogenous analgesia in colitis. J Neuroinflammation. 2022;19:7.
   PubMedGoogle Scholar
• Salaga M, Mokrowiecka A, Jacenik D, et al. Systemic administration of sialorphin attenuates experimental colitis in mice via interaction with mu and kappa opioid receptors. J Crohns Colitis. 2017;11:988–998.
   PubMedGoogle Scholar
• Sałaga M, Sobczak M, Fichna J. Inhibition of proteases as a novel therapeutic strategy in the treatment of metabolic, inflammatory and functional diseases of the gastrointestinal tract. Drug Discov Today. 2013;18:708–715.
   PubMedGoogle Scholar
• Twardowska A, Makaro A, Binienda A, et al. Preventing bacterial translocation in patients with leaky gut syndrome. Nutrition and Pharmacological Treatment Options Int J Mol Sci. 23 2022;23(6):3204.
   Google Scholar